If the sentiment expressed in the CNBC article helps convince US policy makers to reduce funding for cancer vaccine therapy then it will make the treatment inaccessible to many in the US.
CNBC Special Report - Medicare Policies May Be Saying No Cost Is Too Great
The report refers to Provenge and Dendreon as an example:
"The cutting-edge technology has no significant side effects, but also happens to have almost no measurable effects of any kind: Tumors don?t shrink. Blood tests are unchanged. But men with otherwise intractable prostate cancer who get the procedure tend to live a bit longer ?4.1 months is the median.
And it?s very, very expensive ? about $93,000 for a course of treatment."
http://www.cnbc.com/id/42933087
is cancer vaccine treatment worth the cost?
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.100(23.0%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 40.0¢ | 23.0¢ | $16.23M | 50.19M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 704297 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 102135 | 2 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |